<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2013071814047N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2013-11-07</date_registration>
      <primary_sponsor>Vice chancellor for research, Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effect of Acetaminophen and Ibuprofen in pain relief following Adenotonsillectomy.</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of Acetaminophen and Ibuprofen in pain relief and complication management following Adenotonsillectomy in 4-10 year old children.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2013-06-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>50</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/13747</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Other design features: This study has been called triple blind. Treatment allocation is  revealed neither to patients nor to the researcher who fills out the questionnaires.  In addition the individuals who access the data do not know which treatment is assigned to each patient.</study_design>
      <phase>3</phase>
      <hc_freetext>Adenotonsillectomy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: Syrup Ibuprofen 10mg/ kg orally, once an hour before surgery and then every 6 hour for 3 days was used. This syrup manufacturing company is Hakim co. in Iran and its concentration is 100 mg per 5 ml. Intervention 2: Intervention group 2: Syrup Acetaminophen 15mg/ kg orally, once an hour before surgery and then every 6 hours for 3 days was used. This syrup manufacturing company is Kimidaru co. in Iran and its concentration is 120 mg per 5 ml.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fatemeh Mirashrafi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Imam Khomeini Hospital, Dr. Mohammad Gharib Ave., Keshavarz Blvd., Enghelab St.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 6658 1628</telephone>
        <email>f-mirashrafi@sina.tums.ac.ir</email>
        <affiliation>ENT research center, Imam Khomeini Hospital</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Fatemeh Mirashrafi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Imam Khomeini Hospital, Dr. Mohammad Gharib Ave., Keshavarz Blvd., Enghelab St.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 6658 1628</telephone>
        <email>f-mirashrafi@sina.tums.ac.ir</email>
        <affiliation>ENT research center, Imam Khomeini Hospital</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria:&#13;
1-	No Allergy to Non Steroid Anti-Inflammatory Drugs &#13;
2-	No History of coagulopathy   &#13;
3-	No Renal and Hepatic disorder&#13;
4-	No Severe Asthma (recently admission or treatment with oral corticosteroid)&#13;
5-	No Family history of coagulopathy&#13;
6-	No Evidence of Mental retardation &#13;
Exclusion Criteria:&#13;
1-	 Severe and uncontrollable bleeding during and after surgery&#13;
2-	 Severe pain after surgery which needs additional analgesic</inclusion_criteria>
      <agemin>4 years</agemin>
      <agemax>10 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>J35.1,J35.</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Enlargement of tonsils, Enlargement of adenoids</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: Syrup Ibuprofen 10mg/ kg orally, once an hour before surgery and then every 6 hour for 3 days was used. This syrup manufacturing company is Hakim co. in Iran and its concentration is 100 mg per 5 ml.</i_keyword>
      <i_keyword>Intervention group 2: Syrup Acetaminophen 15mg/ kg orally, once an hour before surgery and then every 6 hours for 3 days was used. This syrup manufacturing company is Kimidaru co. in Iran and its concentration is 120 mg per 5 ml.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain score. Timepoint: Six hours postoperative, at the end of first postoperative day, at the end of second postoperative day. Method of measurement: with visual analogue pain scale (1-10 score).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Intraoperative bleeding volume. Timepoint: During the surgery. Method of measurement: Amount of bleeding in CC, according to the number of sterile gases that is used during the surgery and amount of blood at suction bottle.</sec_outcome>
      <sec_outcome>Bleeding at the first postoperative day. Timepoint: At the end of the first postoperative day. Method of measurement: questionnaire.</sec_outcome>
      <sec_outcome>Bleeding during  the first postoperative week. Timepoint: At the end of first postoperative week. Method of measurement: questionnaire.</sec_outcome>
      <sec_outcome>Nausea. Timepoint: At the end of first postoperative  day and at the end of first postoperative week. Method of measurement: questionnaire.</sec_outcome>
      <sec_outcome>Vomiting. Timepoint: At the end of first postoperative day and at the end of first postoperative week. Method of measurement: questionnaire.</sec_outcome>
      <sec_outcome>Time to start eating of oral liquids. Timepoint: At the end of first postoperative week. Method of measurement: questionnaire.</sec_outcome>
      <sec_outcome>Time to start eating of semisolid foods. Timepoint: At the end of first postoperative week. Method of measurement: questionnaire.</sec_outcome>
      <sec_outcome>Time to start eating of solid foods. Timepoint: At the end of first postoperative week. Method of measurement: questionnaire.</sec_outcome>
      <sec_outcome>Time to going back to their normal life. Timepoint: At the end of first postoperative week. Method of measurement: questionnaire.</sec_outcome>
      <sec_outcome>Overall satisfaction of recovery. Timepoint: At the end of first postoperative week. Method of measurement: Questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice chancellor for research, Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2012-07-11</approval_date>
        <contact_name>Ethics committee of Tehran University of Medical Sciences</contact_name>
        <contact_address>Sixth floor, central organization of University, next to Ghods Ave, Keshavarz Blvd. Tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
